DE60128914D1 - Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation - Google Patents

Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Info

Publication number
DE60128914D1
DE60128914D1 DE60128914T DE60128914T DE60128914D1 DE 60128914 D1 DE60128914 D1 DE 60128914D1 DE 60128914 T DE60128914 T DE 60128914T DE 60128914 T DE60128914 T DE 60128914T DE 60128914 D1 DE60128914 D1 DE 60128914D1
Authority
DE
Germany
Prior art keywords
human origin
platelet aggregation
antibodies
inhibit platelet
iiia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128914T
Other languages
English (en)
Other versions
DE60128914T2 (de
Inventor
Claudia Buettner
Meike Schwarz
Stefan Knackmuss
Karlheinz Peter
Peter Roettgen
Melvyn Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics AG filed Critical Affimed Therapeutics AG
Application granted granted Critical
Publication of DE60128914D1 publication Critical patent/DE60128914D1/de
Publication of DE60128914T2 publication Critical patent/DE60128914T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60128914T 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation Expired - Lifetime DE60128914T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123851A EP1300419B1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Publications (2)

Publication Number Publication Date
DE60128914D1 true DE60128914D1 (de) 2007-07-26
DE60128914T2 DE60128914T2 (de) 2008-05-08

Family

ID=8178855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128914T Expired - Lifetime DE60128914T2 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Country Status (7)

Country Link
US (1) US7812136B2 (de)
EP (1) EP1300419B1 (de)
JP (2) JP4504017B2 (de)
AT (1) ATE364632T1 (de)
DE (1) DE60128914T2 (de)
ES (1) ES2288900T3 (de)
WO (1) WO2003031476A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2436170T3 (es) * 2003-12-03 2013-12-27 The Scripps Research Institute Anticuerpos y péptidos específicos de la integrina alfa II beta3
CA2613691A1 (en) * 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
WO2007139208A1 (ja) * 2006-05-26 2007-12-06 Kurume University 血小板の粘着凝集反応に関連する疾患の予防用又は治療用の医薬組成物、および、そのスクリーニング方法
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
EP2704743B1 (de) 2011-05-04 2020-03-11 Omeros Corporation Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP2858659B1 (de) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Prokoagulationsverbindungen
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6686768B2 (ja) * 2015-09-03 2020-04-22 東ソー株式会社 細胞の分離回収方法
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930702536A (ko) 1991-09-17 1993-09-09 히로시 이따가끼 당단백질 IIb/IIIa에 대한 사람 모노클론 항체
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
CN1163599C (zh) * 1997-06-06 2004-08-25 Asat应用科学技术股份公司 抗gpiib/iiia重组抗体
WO2000052054A2 (en) * 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
DE60128914T2 (de) 2008-05-08
US7812136B2 (en) 2010-10-12
JP4504017B2 (ja) 2010-07-14
EP1300419B1 (de) 2007-06-13
US20070218067A1 (en) 2007-09-20
JP2010029203A (ja) 2010-02-12
WO2003031476A1 (en) 2003-04-17
ES2288900T3 (es) 2008-02-01
ATE364632T1 (de) 2007-07-15
JP2005514009A (ja) 2005-05-19
EP1300419A1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
DE60128914D1 (de) Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
BRPI0511008A (pt) agentes de ligação de il-13
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
PH12014501872A1 (en) P-cadherin antibodies
DE602006013029D1 (de) Anti-egfr-antikörper
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
ATE481979T1 (de) Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
MX2009011407A (es) Antagonistas crig.
WO2009055669A3 (en) Monoclonal antibodies against activated and unactivated protein c
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
EA200702197A1 (ru) Противораковая комбинация, содержащая производные замещённого акрилоилдистамицина и антитела, ингибирующие факторы роста или их рецепторы
EP1408112A4 (de) An die katalytische mt4-mmp-domäne bindender monoklonaler antikörper
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13

Legal Events

Date Code Title Description
8364 No opposition during term of opposition